
	Year Ended December 31,
(in thousands)	2024	2023
Non-cash charges (1) (2)	$7,329	$55,723
Cash charges
Personnel related costs (3)	1,993	9,430
Contract costs (4)	566	10,000
Total restructuring related costs	$9,888	$75,153

_____________________________________________________

(1)For the year ended December 31, 2024, non-cash charges principally relate to a $6.8 million loss on disposal of

software license used to support the product feature that was sunset and presented within sales and marketing

expenses in the consolidated statement of operations.

(2)For the year ended December 31, 2023, non-cash charges principally relate to (i) $46.7 million amortization of

acquired intangible assets related to vitaCare and capitalized internal-use software that were accelerated through

December 31, 2023 and presented within depreciation and amortization in the consolidated statement of

operations; and (ii) a $7.0 million loss on the disposal of certain capitalized software that were not yet ready for

their intended use and presented within product development and technology expenses in the consolidated

statement of operations. Non-cash charges also included $1.3 million loss on disposal of allocated goodwill

(3)Cash charges on personnel related costs consist of termination charges arising from severance obligations,

continuation of salaries and benefits over a notification period during which impacted employees did not provide

active service, and other customary employee benefit payments in connection with a reduction in force. For the

year ended December 31, 2024, the majority of these costs were recognized in product development and

technology expenses in the consolidated statement of operations. For the year ended December 31, 2023, $4.5

million of these costs were recognized in cost of revenue, $2.4 million in product development and technology, $2.2

million in sales and marketing with the remainder in general and administrative expenses in the consolidated

(4)For the year ended December 31, 2023, this cash payment relates to the termination of certain contracts with a

pharma manufacturer solutions client, which was recognized as a reduction of revenue in the consolidated